190 related articles for article (PubMed ID: 38663936)
21. Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: A systematic review of the literature.
Zilli T; Dal Pra A; Kountouri M; Miralbell R
Cancer Treat Rev; 2016 May; 46():35-41. PubMed ID: 27082769
[TBL] [Abstract][Full Text] [Related]
22. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.
de Crevoisier R; Slimane K; Messai T; Wibault P; Eschwege F; Bossi A; Koscielny S; Bridier A; Massard C; Fizazi K
Ann Oncol; 2010 Apr; 21(4):808-814. PubMed ID: 19825885
[TBL] [Abstract][Full Text] [Related]
23. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
[TBL] [Abstract][Full Text] [Related]
24. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
25. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial.
Sargos P; Mottet N; Bellera C; Richaud P
BJU Int; 2020 Jun; 125(6):810-816. PubMed ID: 30946523
[TBL] [Abstract][Full Text] [Related]
26. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.
Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A
Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110
[TBL] [Abstract][Full Text] [Related]
27. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
Boorjian SA; Karnes RJ; Viterbo R; Rangel LJ; Bergstralh EJ; Horwitz EM; Blute ML; Buyyounouski MK
Cancer; 2011 Jul; 117(13):2883-91. PubMed ID: 21692049
[TBL] [Abstract][Full Text] [Related]
29. Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer.
Qin C; Wang J; Du Y; Xu T
Front Endocrinol (Lausanne); 2022; 13():1055826. PubMed ID: 36506053
[TBL] [Abstract][Full Text] [Related]
30. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
31. Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.
Pal SK; Moreira D; Won H; White SW; Duttagupta P; Lucia M; Jones J; Hsu J; Kortylewski M
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013891
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.
Xu P; Yang JC; Chen B; Nip C; Van Dyke JE; Zhang X; Chen HW; Evans CP; Murphy WJ; Liu C
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37147019
[TBL] [Abstract][Full Text] [Related]
33. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer.
Benzon B; Glavaris SA; Simons BW; Hughes RM; Ghabili K; Mullane P; Miller R; Nugent K; Shinder B; Tosoian J; Fuchs EJ; Tran PT; Hurley PJ; Vuica-Ross M; Schaeffer EM; Drake CG; Ross AE
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):126-136. PubMed ID: 29556048
[TBL] [Abstract][Full Text] [Related]
34. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer.
Mohiuddin JJ; Narayan V; Venigalla S; Vapiwala N
Brachytherapy; 2019; 18(3):322-331. PubMed ID: 30862436
[TBL] [Abstract][Full Text] [Related]
35. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
36. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
Nguyen QN; Levy LB; Lee AK; Choi SS; Frank SJ; Pugh TJ; McGuire S; Hoffman K; Kuban DA
Cancer; 2013 Sep; 119(18):3265-71. PubMed ID: 23798338
[TBL] [Abstract][Full Text] [Related]
38. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice.
Payne H; McMenemin R; Bahl A; Greene D; Staffurth J
Int J Clin Pract; 2019 Sep; 73(9):1-6. PubMed ID: 30414348
[TBL] [Abstract][Full Text] [Related]
39. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
40. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
Kishan AU; Steigler A; Denham JW; Zapatero A; Guerrero A; Joseph D; Maldonado X; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Tilki D; Karnes RJ; Tosoian JJ; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Jiang T; Ma TM; Xiang M; Philipson R; Chang A; Kupelian PA; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Boutros PC; Horwitz EM; Tendulkar RD; Spratt DE; Romero T
JAMA Oncol; 2022 Mar; 8(3):e216871. PubMed ID: 35050303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
